Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CNS mitochondria in neurodegenerative disorders.

× No keyword cloud information.

6 in total

1. 5-hydroxytryptamine 1F Receptor Agonist Induces Mitochondrial Biogenesis and Promotes Recovery from Spinal Cord Injury.

Authors: Epiphani C Simmons; Natalie E Scholpa; Kristan H Cleveland; Rick G Schnellmann
Journal: J Pharmacol Exp Ther Date: 2019-11-27 Impact factor: 4.030

Review 2. Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target.

Authors: Natalie E Scholpa; Rick G Schnellmann
Journal: J Pharmacol Exp Ther Date: 2017-09-21 Impact factor: 4.030

Review 3. Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors: Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal: Exp Neurol Date: 2020-04-11 Impact factor: 5.330

4. Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β₂-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury.

Authors: Natalie E Scholpa; Hannah Williams; Wenxue Wang; Daniel Corum; Aarti Narang; Stephen Tomlinson; Patrick G Sullivan; Alexander G Rabchevsky; Rick G Schnellmann
Journal: J Neurotrauma Date: 2018-11-16 Impact factor: 5.269

5. 5-HT_1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease.

Authors: Natalie E Scholpa; Mary K Lynn; Daniel Corum; Heather A Boger; Rick G Schnellmann
Journal: Br J Pharmacol Date: 2017-12-22 Impact factor: 8.739

6. FDA-approved 5-HT_1F receptor agonist lasmiditan induces mitochondrial biogenesis and enhances locomotor and blood-spinal cord barrier recovery after spinal cord injury.

Authors: Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal: Exp Neurol Date: 2021-04-10 Impact factor: 5.620

6 in total

CNS mitochondria in neurodegenerative disorders.

1. 5-hydroxytryptamine 1F Receptor Agonist Induces Mitochondrial Biogenesis and Promotes Recovery from Spinal Cord Injury.

Review 2. Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target.

Review 3. Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

4. Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury.

5. 5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease.

6. FDA-approved 5-HT1F receptor agonist lasmiditan induces mitochondrial biogenesis and enhances locomotor and blood-spinal cord barrier recovery after spinal cord injury.

4. Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β₂-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury.

5. 5-HT_1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease.

6. FDA-approved 5-HT_1F receptor agonist lasmiditan induces mitochondrial biogenesis and enhances locomotor and blood-spinal cord barrier recovery after spinal cord injury.